Evidence mapPaperPMID 35552683Full record

ReviewEndocrine reviews2022

Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy.

Angeliki M Angelidi, Matthew J Belanger, Alexander Kokkinos, Chrysi C Koliaki, Christos S Mantzoros

Open access · bronzeAbstract readReview
In one paragraph

Review in Endocrine reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 1 pooled it
14.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 1 synthesis or guideline pooled it, 118 citations in OpenAlex.

  1. Pooled it
  2. Defining Predictors of Weight Loss Response to Lorcaserin.The Journal of clinical endocrinology and metabolism · 2023
    Trial
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Review
  8. The Genetic Blueprint of Obesity: From Pathogenesis to Novel Therapies.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025
    Review
  9. Advances and future directions in endoscopic bariatric therapies.World journal of gastrointestinal endoscopy · 2025
    Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Angeliki M AngelidiSection of Endocrinology, VA Boston Healthcare System, Harvard Medical School, Boston, MA, USA.
Matthew J BelangerDepartment of Medicine Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Alexander KokkinosFirst Department of Propaedeutic Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece.
Chrysi C KoliakiFirst Department of Propaedeutic Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece.
Christos S MantzorosSection of Endocrinology, VA Boston Healthcare System, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-3755-8158
Beth Israel Deaconess Medical Center · USNational and Kapodistrian University of Athens · GR

Funding

NIDDK NIH HHS K24 DK081913
6 · The paper itself

Abstract

Recent insights into the pathophysiologic underlying mechanisms of obesity have led to the discovery of several promising drug targets and novel therapeutic strategies to address the global obesity epidemic and its comorbidities. Current pharmacologic options for obesity management are largely limited in number and of modest efficacy/safety profile. Therefore, the need for safe and more efficacious new agents is urgent. Drugs that are currently under investigation modulate targets across a broad range of systems and tissues, including the central nervous system, gastrointestinal hormones, adipose tissue, kidney, liver, and skeletal muscle. Beyond pharmacotherapeutics, other potential antiobesity strategies are being explored, including novel drug delivery systems, vaccines, modulation of the gut microbiome, and gene therapy. The present review summarizes the pathophysiology of energy homeostasis and highlights pathways being explored in the effort to develop novel antiobesity medications and interventions but does not cover devices and bariatric methods. Emerging pharmacologic agents and alternative approaches targeting these pathways and relevant research in both animals and humans are presented in detail. Special emphasis is given to treatment options at the end of the development pipeline and closer to the clinic (ie, compounds that have a higher chance to be added to our therapeutic armamentarium in the near future). Ultimately, advancements in our understanding of the pathophysiology and interindividual variation of obesity may lead to multimodal and personalized approaches to obesity treatment that will result in safe, effective, and sustainable weight loss until the root causes of the problem are identified and addressed.

Indexed as

Anti-Obesity AgentsAnimalsGenetic TherapyHomeostasisHumansObesityWeight LossAnti-Obesity Agentsadipose tissuecentral nervous systemgastrointestinal hormonesnanotherapynovel drug delivery systemsobesitypharmacotherapy

Identifiers

PMID35552683
PMCPMC9113190
OpenAlexW3209709155

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.